Publications and Presentations

Corvus is committed to driving science and medicine and helping patients. We promptly and efficiently communicate our preclinical and clinical findings to the scientific, medical and patient communities because we believe disseminating knowledge and information is good for patients.

Our scientists and clinical trial investigators have published the following research papers in peer-reviewed journals and presented the following data at scientific congresses.

Presentations


CPI-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, is Well-Tolerated and Active in Patients with T-Cell Lymphoma

Khodadoust M1, Feldman T2, Yoon DH3, Yannakou C4, Radeski D5, Kim YH6, Mehta-Shah N7, Khot A8, Wilcox R9, Kim WS10, Horwitz S11, Buggy J12, Hotson A12, Hill C12, Munneke B12, Mahabhashyam S12, Miller R12, Janc J12 and Mobasher M12

1Division of Medical Oncology, Stanford University School of Medicine, Stanford, CA; 2John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ; 3Asan Medical Center/University of Ulsan College of Medicine, Seoul, Korea, Republic of (South); 4Epworth HealthCare, Melbourne, Australia; 5Linear Clinical Research and Sir Charles Gairdner Hospital, Nedlands, Australia; 6Stanford University School of Medicine and Stanford Cancer Institute, Stanford, CA; 7Division of Medical Oncology, Washington University School of Medicine, St Louis, MO; 8Department of Clinical Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia; 9University of Michigan, Ann Arbor, MI; 10Hematology and Oncology, Department of Medicine, Samsung Medical Center, Seoul, Korea, Republic of (South); 11Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY; 12Corvus Pharmaceuticals, Inc., Burlingame, CA

Poster presentation at the 2020 American Society of Hematology (ASH) 62nd Annual Meeting


Immunotherapy with B cell activating antibody CPI-006 in patients with mild to moderate COVID-19 stimulates anti-SARS-CoV-2 antibody response, memory B cells, and memory T effector cells

Gerard Criner, M.D., Chair & Professor, Thoracic Medicine & Surgery, Lewis Katz School of Medicine at Temple University

Oral presentation at the 2020 Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting


Immunotherapy with B cell activating antibody CPI-006 in patients with mild to moderate COVID-19 stimulates anti-SARS-CoV-2 antibody response, memory B cells, and memory T effector cells

Criner G1, Mobasher M2, Hill C2, Hu S2, Mahabhashyam S2, Brody J3, Marron T3, Willingham S2, Miller R2 

1Temple University Hospital, Philadelphia, PA, USA; 2Corvus Pharmaceuticals Inc, Burlingame, CA, USA; 3Icahn School of Medicine at Mount Sinai, New York, NY, USA 

Poster presentation at the 2020 Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting


CD68+ Tumor-Associated Myeloid Cells as the Target of Adenosine-Induced Gene Products and Predictor of Response to Adenosine Blockade with Ciforadenant (Cifo) in Renal Cell Cancer (RCC)

Voss M1, Hotson A2, Willingham S2, Hughes B3, Mercan J4, Fong L5, Chu M6, George S7, Munneke B2, Mobasher M2, Miller R2

1Memorial Sloan Kettering Cancer Center, New York NY, 2Corvus Pharmaceuticals, Burlingame CA, 3Royal Brisbane Hospital, Brisbane Australia, 4Sylvester Comprehensive Cancer Center, Miami FL, 5UCSF Comprehensive Cancer Center, San Francisco CA,  6Cross Cancer Institute, Alberta Canada, 7Roswell Park Cancer Institute, Buffalo NY

Poster presentation at the American Society of Clinical Oncology ASCO20 Virtual Scientific Program


Adenosine Receptor Blockade with Ciforadenant ± Atezolizumab in Advanced Metastatic Castration Resistant Prostate Cancer (mCRPC)

Fong L1, Chu M2, George S3, Hughes B4, Carthon B5, Merchan J6, Harshman L7, Munneke B8, Kwei L8, Hotson A8, Mobasher M8, Miller R8

1UCSF Comprehensive Cancer Center, San Francisco CA, 2Cross Cancer Institute, Alberta Canada, 3Roswell Park Cancer Institute, Buffalo NY, 4Royal Brisbane Hospital, Brisbane Australia, 5Winship Cancer Institute, Atlanta GA, 6Sylvester Comprehensive Cancer Center, Miami FL, 7Dana-Farber Cancer Institute, Boston MA, 8Corvus Pharmaceuticals, Burlingame CA

Poster presentation at the American Society of Clinical Oncology 2020 Genitourinary Cancers Symposium (ASCO-GU)


CPI-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor
Pre-clinical Characterization and Interim Results of a Phase I/Ib Dose-Escalation Trial in Patients with Relapsed/Refractory T-Cell Lymphoma

Mehrdad Mobasher, MD, MPH Chief Medical Officer

Oral Presentation at the 12th Annual T-Cell Lymphoma Forum in La Jolla, California, February 1, 2020


Preliminary Clinical Data from a Phase 1 Trial with CPI-818, A Selective ITK Inhibitor that Preferentially Blocks the Growth of T Lymphoma Cells 

Patrick P. Ng, PhD, Corvus Senior Scientist

Poster Presentation at the American Society of Hematology (ASH) 61st  Annual Meeting 2019


Immunobiology and Clinical Activity of CPI-006, an Anti-CD73 Antibody with Immunomodulating Properties in a Phase 1/1b Trial in Advanced Cancers

Jason J. Luke, M.D., FACP, Director of the Cancer Immunotherapeutics Center, Associate Professor of Medicine, the University of Pittsburgh Medical Center and Hillman Cancer Center

Oral presentation at 2019 Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting


Adenosine and AMP Gene Expression Profiles Predict Response to Adenosine Pathway Therapies and Indicate a Need for Dual Blockade of CD73 and A2AR with CD73 Inhibitors

Stephen Willingham, PhD, Corvus Senior Scientist

Poster Presentation at 2019 Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting


Immunobiology, Preliminary Safety and Efficacy of CPI-006, an Anti-CD73 Antibody with Immune Modulating Activity, in a Phase 1 Trial in Advanced Cancers

Jason J. Luke*, John D. Powderly II, Jaime R. Merchan, Minal A. Barve, Andrew N. Hotson, Mehrdad Mobasher, Long Kwei, Gabriel Luciano, Joseph J. Buggy, Emily Piccione, Richard A. Miller

University of Chicago Comprehensive Cancer Center, Chicago, IL; Carolina BioOncology Institute, Huntersville, NC; University of Miami, Miami, FL; Mary Crowley Cancer Research Center, Dallas, TX; Corvus Pharmaceuticals Inc, Burlingame, CA

*Currently at University of Pittsburgh Medical Center 

Oral presentation at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting


Biochemical, Immunologic and In Vivo Preclinical Studies with CPI-818: A Selective Interleukin-2-Inducible T-cell Kinase Inhibitor That Inhibits T-Cell Receptor Signaling, Promotes Th1 Skewing, and is Efficacious in Dogs with T-Cell Lymphomas

James W Janc1,*, C M Hill1, P P Ng1, A N Hotson1, A Madriaga1, T P Dao-Pick1, K S Yeung1, E Verner1, D H Thamm2, R A Miller1 and J J Buggy1

Corvus Pharmaceuticals, Burlingame CA, USA. Flint Animal Cancer Center, Colorado State University, Fort Collins, CO, USA.

Poster presentation at the 11th Annual T-cell Lymphoma Forum, La Jolla, CA, January 10-12, 2019


Interleukin-2-Inducible T-cell Kinase Inhibitors for the Treatment of T-cell Lymphoproliferative Disorders

John C. Reneau, MD, PhD1, Steven R. Hwang, MD2, Carlos A. Murga-Zamalloa, MD1, Joseph J. Buggy, PhD3, James W. Janc, PhDand Ryan A. Wilcox, MD, PhD1

University of Michigan, Ann Arbor, MI; 2 Mayo Clinic, Rochester, MN; 3 Corvus Pharmaceuticals, Inc., Burlingame, CA

Poster presentation at 60th Annual ASH Meeting, San Diego, CA, Dec 1-4th 2018


CPI-818: A Selective Interleukin-2-Inducible T-cell Kinase Inhibitor Has Clinical Activity in Dogs with Spontaneous T-cell Lymphoma

Douglas H. Thamm,1 Kristen M. Weishaar,1 Sunetra Das,1 Antonett Madriaga,2 Craig M. Hill,2 Felicia M. Flicker,2 Bradley H. Wolfe,2 Patrick P. Ng,2 Andrew N. Hotson,2 Richard A. Miller,2 Joseph J. Buggy,2 James W. Janc2

Flint Animal Cancer Center, Colorado State University, Fort Collins, CO USA; Corvus Pharmaceuticals, Burlingame, CA USA

Poster presentation at 30th EORTC-NCI-AACR Symposium, Molecular Targets and Cancer Therapeutics, Dublin IE, Nov 13-16th 2018


Refractory Renal Cell Cancer (RCC) Exhibits High Adenosine A2A Receptor (A2AR) Expression and Prolonged Survival Following Treatment With the A2AR Antagonist CPI-444

Lawrence Fong, M.D., University of California, San Francisco

Oral presentation at 2018 Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting


Preclinical and initial Phase I clinical characterization of CPI-006: an anti-CD73 monoclonal antibody with unique immunostimulatory activity

Emily Piccione, Ph.D., Corvus Pharmaceuticals

Poster presentation at 2018 Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting


Adenosine signature genes associate with tumor regression in renal cell carcinoma (RCC) patients treated with the adenosine A2A receptor (A2AR) antagonist, CPI-444

Drew Hotson, Ph.D., Corvus Pharmaceuticals

Poster presentation at 2018 Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting


Identification of Adenosine Pathway Genes Associated with Response to Therapy with the Adenosine Receptor Antagonist CPI-444

Willingham S1, Hotson A1, Laport G1, Kwei L1, Fong L2, Sznol M3, Powderly J4, Miller R1

Corvus Pharmaceuticals, Burlingame CA, USA, 2 University of California, San Francisco CA, USA, Yale University School of Medicine, New Haven CT, USA, Carolina BioOncology Institute, Huntersville NC, USA

Poster presentation at 2018 European Society for Medical Oncology (ESMO) 2018 Congress


Identification of Adenosine Pathway Genes Associated with Response to Therapy with the Adenosine Receptor Antagonist CPI-444

Stephen Willingham, Ph.D., Corvus Pharmaceuticals

Slide presentation at 2018 European Society for Medical Oncology (ESMO) 2018 Congress


Preclinical Study of Investigational Small Molecule T-cell Signaling Pathway Inhibitor in Companion Dogs Diagnosed with T-cell Lymphoma

Ryan Wilcox, M.D., Ph.D., Assistant Professor at the University of Michigan Comprehensive Cancer Center

Oral presentation at 10th Annual T-Cell Lymphoma Forum (2018)


Clinical Activity of Adenosine A2a Receptor (A2aR) Inhibitor CPI-444 is Associated with Tumor Expression of Adenosine Pathway Genes and Tumor Immune Modulation

Jason J. Luke, M.D., FACP, Assistant Professor of Medicine, University of Chicago Medicine

Oral presentation at Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting (2017)


Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients

Lawrence Fong, M.D., Leader, Cancer Immunotherapy Program, Co-Director, Parker Institute of Cancer Immunotherapy, University of California, San Francisco

Oral presentation at American Society of Clinical Oncology (ASCO) 2017 Annual Meeting


CPI-444, an oral adenosine A2a receptor (A2AR) antagonist, demonstrates clinical activity in patients with advanced solid tumors 

Leisha Emens, M.D., Ph.D., Associate Professor of Oncology, John Hopkins Sidney Kimmel Comprehensive Cancer Center

Oral Presentation at American Association for Cancer Research (AACR) 2017 Annual Meeting


Inhibition of A2AR induces anti-tumor immunity alone and in combination with anti-PD-L1 in preclinical and clinical studies

Stephen Willingham, Ph.D., Corvus Pharmaceuticals 

Poster Presentation at American Association for Cancer Research (AACR) 2017 Annual Meeting


Adenosine signaling through A2AR limits the efficacy of anti-CTLA4 and chemotherapy in preclinical models

Po Y. Ho, Corvus Pharmaceuticals 

Poster Presentation at American Association for Cancer Research (AACR) 2017 Annual Meeting


A novel CD73-blocking antibody reduces production of immunosuppressive adenosine and restores T-cell function

Emily Piccione, Ph.D., Corvus Pharmaceuticals 

Poster Presentation at American Association for Cancer Research (AACR) 2017 Annual Meeting


Publications

The following contains links to certain websites owned and operated by third parties. If you use these links you leave our website. These links are provided for your information and convenience only and are not an endorsement by Corvus Pharmaceuticals, Inc. of the content of such linked websites. Corvus has no control of the content of any linked website and is not responsible for these websites or their content or availability. Corvus therefore makes no warranties or representations, express or implied about such linked websites, the third parties they are owned and operated by or the information contained on them.


Clinical Results with a B Cell Activating Anti-CD73 Antibody for the Immunotherapy of COVID-19

Richard A. Miller, Pramod Guru, Philippe Bauer, Jorge Robles, Christian Tomaszewski, J. Scott Overcash, Michael Waters, Miriam Cameron,Julián Olalla Sierra, James Janc, Jenny A. Rudnick, Shenshen Hu, William B. Jones, Long Kwei, Suresh Mahabhashyam, Stephen B. Willingham, and Gerard Criner

medRxiv doi: 10.1101/2021.09.13.21263406v1


Therapeutic blockade of CXCR2 rapidly clears inflammation in arthritis and atopic dermatitis models: demonstration with surrogate and humanized antibodies

Md Jahangir Alam, Liang Xie, Caroline Ang, Farnaz Fahimi, Stephen B. Willingham, Andrew J. Kueh, Marco J. Herold, Charles R. Mackay, and Remy Robert

mAbs, 2020 12:1, DOI: 10.1080/19420862.2020.1856460


Targeting the A2AR in Cancer; Early Lessons From the Clinic

Willingham SB, Hotson AN, Miller RA

Curr. Opin. Pharmacol. 2020, 53:126–133.


Characterization and Phase 1 Trial of a B Cell Activating Anti-CD73 Antibody for the Immunotherapy of COVID-19

Stephen B. Willingham, Gerard Criner, Craig Hill, Shenshen Hu, Jenny A. Rudnick, Barbara Daine-Matsuoka, Jessica Hsieh, Haider Mashhedi, Andrew N. Hotson, Joshua Brody, Thomas Marron, Emily Piccione, Joseph J. Buggy, Suresh Mahabhashyam, William B. Jones, Mehrdad Mobasher, and Richard A. Miller

medRxiv doi: 10.1101/2020.09.10.20191486

Our Science

We are developing immunology focused medicines that target the most critical cellular elements of the immune system

Join Our Team

Contribute your talent, expertise and desire to learn here at Corvus, where you can help improve the lives of people with cancer, immune disorders and infectious diseases